GSTCD

Across TCGA pan-cancer cohorts, GSTCD Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GSTCD data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GSTCD Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GSTCD expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, BLCA, and UCS are the cancer types where GSTCD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.954	0.827	.021	26	view →
BLCA	OS	Median	All	0.183	0.720	.001	18	view →
UCS	OS	Median	All	0.153	0.687	.019	6	view →
SARC	OS	Median	All	0.175	0.745	.007	6	view →
SKCM	OS	Median	All	1.000	0.777	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GSTCD–UCEC (DFS)

Open the UCEC breakdown →